Tofacitinib an alternative treatment for refractory cutaneous dermatomyositis

Tofacitinib, an oral Janus kinase (JAK)-1/3 inhibitor approved for treating rheumatoid arthritis, was beneficial in treating cutaneous dermatomyositis in three patients who had failed traditional...
Source: Rheumatology News - Category: Rheumatology Source Type: research